Celldex Therapeutics has initiated an underwritten public offering of its common stock, including a potential 15% additional share option for underwriters. The company plans to use the proceeds to support the commercial launch of barzolvolimab for chronic spontaneous urticaria (CSU) in the U.S., advance clinical and preclinical development of its drug candidates, expand its bispecific antibody platform, and fund general corporate activities. The offering's final terms depend on market conditions and will be detailed in a forthcoming prospectus supplement. This move aims to strengthen Celldex's financial position as it progresses its pipeline of antibody-based therapies targeting severe inflammatory and autoimmune diseases.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
